0001209191-18-047808.txt : 20180821 0001209191-18-047808.hdr.sgml : 20180821 20180821175208 ACCESSION NUMBER: 0001209191-18-047808 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170613 FILED AS OF DATE: 20180821 DATE AS OF CHANGE: 20180821 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: YORDON JEFFREY CENTRAL INDEX KEY: 0001189013 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38112 FILM NUMBER: 181031063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Athenex, Inc. CENTRAL INDEX KEY: 0001300699 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 431985966 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1001 MAIN STREET STREET 2: SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 BUSINESS PHONE: 716-898-8625 MAIL ADDRESS: STREET 1: 1001 MAIN STREET STREET 2: SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 FORMER COMPANY: FORMER CONFORMED NAME: Kinex Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20131223 FORMER COMPANY: FORMER CONFORMED NAME: Kinex Pharmaceuticals LLC DATE OF NAME CHANGE: 20040817 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2017-06-13 2017-06-21 0 0001300699 Athenex, Inc. ATNX 0001189013 YORDON JEFFREY C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600 BUFFALO NY 14203 0 1 0 0 See Remarks Stock Option (Right to Buy) 11.00 2017-06-13 4 A 0 230000 0.00 A 2027-06-13 Common Stock 230000 230000 D This option was previously reported by Mr. Yordon. This amendment is being filed to correct the transaction date, exercise date, and expiration date. This option vests in three equal annual installments beginning on June 13, 2018. Officer: Chief Operating Officer and President, Athenex Pharmaceutical Division /s/ Teresa Bair, Attorney-in-Fact 2018-08-21